Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/93676
Title: | Targeting inflammasome activation in COVID-19 : delivery of RNA interference-based therapeutic molecules | Authors: | Gedefaw, L Ullah, S Lee, TMH Yip, SP Huang, CL |
Issue Date: | Dec-2021 | Source: | Biomedicines, Dec. 2021, v. 9, no.12, 1823 | Abstract: | Mortality and morbidity associated with COVID-19 continue to be significantly high worldwide, owing to the absence of effective treatment strategies. The emergence of different variants of SARS-CoV-2 is also a considerable source of concern and has led to challenges in the development of better prevention and treatment strategies, including vaccines. Immune dysregulation due to pro-inflammatory mediators has worsened the situation in COVID-19 patients. Inflammasomes play a critical role in modulating pro-inflammatory cytokines in the pathogenesis of COVID-19 and their activation is associated with poor clinical outcomes. Numerous preclinical and clinical trials for COVID-19 treatment using different approaches are currently underway. Targeting different inflammasomes to reduce the cytokine storm, and its associated complications, in COVID-19 patients is a new area of research. Non-coding RNAs, targeting inflammasome activation, may serve as an effective treatment strategy. However, the efficacy of these therapeutic agents is highly dependent on the delivery system. MicroRNAs and long non-coding RNAs, in conjunction with an efficient delivery vehicle, present a potential strategy for regulating NLRP3 activity through various RNA interference (RNAi) mechanisms. In this regard, the use of nanomaterials and other vehicle types for the delivery of RNAi-based therapeutic molecules for COVID-19 may serve as a novel approach for enhancing drug efficacy. The present review briefly summarizes immune dysregulation and its consequences, the roles of different non-coding RNAs in regulating the NLRP3 inflammasome, distinct types of vectors for their delivery, and potential therapeutic targets of microRNA for treatment of COVID-19. | Keywords: | Inflammasome RNA interference COVID-19 Non-coding RNAs Molecular targets |
Publisher: | MDPI AG | Journal: | Biomedicines | ISSN: | 2227-9059 | DOI: | 10.3390/biomedicines9121823 | Rights: | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license https://creativecommons.org/licenses/by/4.0/). The following publication Gedefaw, L., Ullah, S., Lee, T. M., Yip, S. P., & Huang, C. L. (2021). Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules. Biomedicines, 9(12), 1823 is available at https://doi.org/10.3390/biomedicines9121823 |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
biomedicines-09-01823.pdf | 2.29 MB | Adobe PDF | View/Open |
Page views
56
Last Week
1
1
Last month
Citations as of May 5, 2024
Downloads
20
Citations as of May 5, 2024
SCOPUSTM
Citations
7
Citations as of May 3, 2024
WEB OF SCIENCETM
Citations
6
Citations as of May 2, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.